Common questions about Glycambi (FAQ)
Q: How is Glycambi different from older treatments for my condition?
A: Official regulatory documents describe Glycambi as a combination of two medicines that work in different ways. One component (Empagliflozin) helps the kidneys remove excess glucose from the body, while the other (Linagliptin) increases the release of insulin when blood sugar is high. This dual mechanism is a recognized approach that differs from treatments that rely on only one pathway.
Q: Is Glycambi safe for elderly patients to use?
A: Regulatory information indicates that use in patients aged 75 years and older may require caution or specific monitoring. This is due to documentation showing a higher occurrence of adverse reactions related to volume depletion and reduced kidney function in this age group. Regulatory information primarily focuses on the increased risk of adverse reactions rather than specific dose details for this population.
Q: Does Glycambi cause changes in body weight?
A: Clinical studies tracked patterns of change in body weight in the patient population over the study periods. While specific average weight change findings are not usually detailed in general patient-facing regulatory summaries, weight was one of the clinical markers monitored during the trials.
Q: What are the signs of a serious allergic reaction to Glycambi?
A: Signs of severe allergic reactions like anaphylaxis or angioedema (swelling) include swelling of the face, tongue, or throat. Official warnings also advise looking out for the development of blisters or erosions on the skin (bullous pemphigoid). These symptoms are considered medical emergencies that require prompt evaluation.
Q: Why do official documents say that special monitoring is needed for patients on Glycambi?
A: Official documents advise monitoring patients for signs of volume depletion (dehydration) and acute kidney injury. Additionally, ketone monitoring may be considered in situations that increase the risk of diabetic ketoacidosis (DKA), such as acute illness or surgery.
Q: How long do people usually need to continue treatment with Glycambi?
A: According to official prescribing information, the medicine is intended for long-term therapy to manage the patient's condition. However, the medicine is recommended to be temporarily withheld prior to specific medical procedures or surgery associated with prolonged fasting.
Q: Is Glycambi considered a 'high-risk' medication?
A: Regulatory documents carry specific Warnings and Precautions for serious and potentially life-threatening adverse events. These include conditions like Diabetic Ketoacidosis (DKA), Acute Pancreatitis, and Fournier's Gangrene, which means that the regulatory information emphasizes awareness and monitoring for symptoms.
Q: What is the difference between Glycambi and a placebo in clinical trials?
A: Clinical trials measured the effectiveness of Glycambi by comparing patient outcomes to those receiving a placebo (an inactive substance). Researchers specifically tracked measured changes in clinical markers like Glycosylated Hemoglobin ( HbA1c) and Fasting Plasma Glucose (FPG) to assess how the drug performed.
Q: Has Glycambi been approved for use in countries outside the US, like Europe or Canada?
A: Yes, official product information confirms that the medicine has been authorized for use in the European Union (EU) and is regulated by agencies such as the European Medicines Agency (EMA). This confirms its authorization and regulatory compliance in these regions.
Q: What percentage of people experience the most common side effect of Glycambi?
A: The most common adverse reactions, such as urinary tract infections, were reported in a documented frequency range in clinical trials. According to official product information, this means they were reported in more than 1% but less than 10% of people who participated in the studies.
Q: Do I need to get regular blood tests while I am taking Glycambi?
A: Regulatory documents recommend the assessment of renal function (kidney health) before starting the medication and periodically during therapy. Monitoring blood glucose levels is also typically necessary as part of standard diabetes management.
Q: Have there been any long-term follow-up safety reports published for Glycambi?
A: Official study information notes that there is limited data available on the long-term safety and durability of response specifically for the fixed-dose combination beyond intermediate-term periods. Therefore, the evidence for the long-term effects of the combination remains limited in current regulatory documentation.
Q: Are there different forms or strengths of Glycambi available?
A: Yes, official prescribing information lists the medicine as being available as film-coated tablets in two different dosage strengths. Regulatory documents indicate these different strengths are available.
Q: Does Glycambi interact with common over-the-counter pain relievers like ibuprofen?
A: Patient information for one of the drug's components (Empagliflozin) notes that it is generally safe to take with common painkillers such as paracetamol and ibuprofen. Patients are advised to review the official patient information leaflet for complete details on all interactions.
Q: Can I drink alcohol while I am on Glycambi treatment?
A: Official patient information advises that drinking alcohol may increase the risk of your blood sugar levels becoming too low (hypoglycemia). Patients may consider discussing their alcohol use with a healthcare professional as part of their overall treatment plan.
Q: Is it common to feel unusually tired when first starting Glycambi?
A: Unusual fatigue or sleepiness is noted in regulatory warnings as a non-specific symptom that should be monitored. It may be a sign consistent with a serious condition, such as diabetic ketoacidosis (DKA), and should be brought to the attention of a healthcare professional.
Q: Does Glycambi affect normal sleep patterns?
A: Official warnings note that unusual sleepiness or tiredness is a non-specific symptom that may be consistent with serious conditions like diabetic ketoacidosis (DKA). Patients are generally advised to be aware of this symptom as part of monitoring for serious adverse reactions.
Q: Are there any restrictions on operating a car or machinery while using Glycambi?
A: Official patient information recommends caution before driving or operating machinery until the individual is aware of how the medicine may affect them. This is especially important when taking Glycambi with other diabetes medicines that may increase the risk of low blood sugar.
Q: Why is Glycambi described as not being suitable for people with certain heart issues?
A: Regulatory documents advise that the risks and benefits should be considered in patients who are at risk for heart failure. This is because heart failure has been observed with other medicines that belong to the same DPP-4 inhibitor class as one of Glycambi’s components.
Q: Does Glycambi interact with common vitamins or herbal supplements?
A: Official patient information notes that there is very little available information about taking one of the drug's components (Empagliflozin) with herbal remedies and supplements. Some supplements, like ginseng, may have the potential to cause low blood sugar.
Q: What happens in general if someone stops taking Glycambi suddenly?
A: Official product information notes that the medicine may need to be temporarily discontinued for specific medical procedures or acute illnesses that predispose the patient to ketoacidosis. Resumption of the medicine is typically done when the patient is clinically stable, under the guidance of a health professional.
Q: Is Glycambi used for more than the main condition it was approved for?
A: Regulatory documents state that the medicine is indicated as an adjunct to diet and exercise to improve glycemic control only in adults with Type 2 diabetes mellitus. This is the single, approved use for the drug.
Q: Is it true that Glycambi can cause problems like stomach pain or nausea?
A: Yes, official warnings list nausea, vomiting, and abdominal pain as signs that may be consistent with serious conditions. These include Diabetic Ketoacidosis (DKA) or Pancreatitis, and are symptoms that patients are generally advised to report to a healthcare professional.
Q: Do all drug interactions with Glycambi only happen with other prescription drugs?
A: Official interaction information identifies prescription medications such as diuretics and insulin secretagogues as potential interacting agents. Patient information sources may also address potential interactions with certain herbal supplements that could affect blood sugar levels, meaning not all interactions involve prescription drugs.
